Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland
Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major p...
Gespeichert in:
Veröffentlicht in: | Epilepsia (Copenhagen) 2002-11, Vol.43 (11), p.1410-1420 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1420 |
---|---|
container_issue | 11 |
container_start_page | 1410 |
container_title | Epilepsia (Copenhagen) |
container_volume | 43 |
creator | Stables, James P. Bertram, Edward H. White, H. Steve Coulter, Douglas A. Dichter, Marc A. Jacobs, Margaret P. Loscher, Wolfgang Lowenstein, Daniel H. Moshe, Solomon L. Noebels, Jeffrey L. Davis, Mirian |
description | Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed.
Methods: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies.
Results: At the end of the 2‐day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure.
Conclusions: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments. |
doi_str_mv | 10.1046/j.1528-1157.2002.06702.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72675779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72675779</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3612-dab2f9e42a30d34bdc74214622032ba9b4930c9356b8c3e3370e56c09e18446a3</originalsourceid><addsrcrecordid>eNqNkElPwzAQhS0EomX5C8gnTqSMl9gJEgeoClQqixAIcbKyTKAlxcFuRfvvcWgkrlzGM_Z7z6OPEMpgwECq09mAxTyJGIv1gAPwASgd6mqL9LsHpbdJH4CJKI0T6JE972cAoJUWu6THuORCpKJPXm9tibWnlXV01ExrbPyaZp9lNyzsG36in_oz-oiNdQtaOTuni3ekd-Mb-mLdh3-3zQm9xHDny-yE3mZuXYeEA7JTZbXHw-7cJ89Xo6fhTTS5vx4PLyZRIRTjUZnlvEpR8kxAKWReFlpyJhXnIHiepblMBRSpiFWeFAKF0ICxKiBFlkipMrFPjje5jbNfS_QLM5_6AuuwA9qlN5orHWudBmGyERbOeu-wMo2bzsO2hoFpsZqZaemZFqtpsZpfrGYVrEfdH8t8juWfseMYBOcbwXegtv53sBk9jNtO_AAqF4Tn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72675779</pqid></control><display><type>article</type><title>Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland</title><source>Wiley Free Content</source><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Stables, James P. ; Bertram, Edward H. ; White, H. Steve ; Coulter, Douglas A. ; Dichter, Marc A. ; Jacobs, Margaret P. ; Loscher, Wolfgang ; Lowenstein, Daniel H. ; Moshe, Solomon L. ; Noebels, Jeffrey L. ; Davis, Mirian</creator><creatorcontrib>Stables, James P. ; Bertram, Edward H. ; White, H. Steve ; Coulter, Douglas A. ; Dichter, Marc A. ; Jacobs, Margaret P. ; Loscher, Wolfgang ; Lowenstein, Daniel H. ; Moshe, Solomon L. ; Noebels, Jeffrey L. ; Davis, Mirian</creatorcontrib><description>Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed.
Methods: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies.
Results: At the end of the 2‐day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure.
Conclusions: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments.</description><identifier>ISSN: 0013-9580</identifier><identifier>EISSN: 1528-1167</identifier><identifier>DOI: 10.1046/j.1528-1157.2002.06702.x</identifier><identifier>PMID: 12423393</identifier><language>eng</language><publisher>Boston, MA, USA: Blackwell Science Inc</publisher><subject>Animals ; Anticonvulsants - therapeutic use ; Antiepileptogenesis ; Child, Preschool ; Disease Models, Animal ; Drug Resistance ; Epilepsy ; Epilepsy - drug therapy ; Epilepsy - etiology ; Humans ; Pediatric epilepsy ; Resistant epilepsy ; Technology, Pharmaceutical - methods</subject><ispartof>Epilepsia (Copenhagen), 2002-11, Vol.43 (11), p.1410-1420</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3612-dab2f9e42a30d34bdc74214622032ba9b4930c9356b8c3e3370e56c09e18446a3</citedby><cites>FETCH-LOGICAL-c3612-dab2f9e42a30d34bdc74214622032ba9b4930c9356b8c3e3370e56c09e18446a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1528-1157.2002.06702.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1528-1157.2002.06702.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12423393$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stables, James P.</creatorcontrib><creatorcontrib>Bertram, Edward H.</creatorcontrib><creatorcontrib>White, H. Steve</creatorcontrib><creatorcontrib>Coulter, Douglas A.</creatorcontrib><creatorcontrib>Dichter, Marc A.</creatorcontrib><creatorcontrib>Jacobs, Margaret P.</creatorcontrib><creatorcontrib>Loscher, Wolfgang</creatorcontrib><creatorcontrib>Lowenstein, Daniel H.</creatorcontrib><creatorcontrib>Moshe, Solomon L.</creatorcontrib><creatorcontrib>Noebels, Jeffrey L.</creatorcontrib><creatorcontrib>Davis, Mirian</creatorcontrib><title>Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland</title><title>Epilepsia (Copenhagen)</title><addtitle>Epilepsia</addtitle><description>Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed.
Methods: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies.
Results: At the end of the 2‐day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure.
Conclusions: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments.</description><subject>Animals</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Antiepileptogenesis</subject><subject>Child, Preschool</subject><subject>Disease Models, Animal</subject><subject>Drug Resistance</subject><subject>Epilepsy</subject><subject>Epilepsy - drug therapy</subject><subject>Epilepsy - etiology</subject><subject>Humans</subject><subject>Pediatric epilepsy</subject><subject>Resistant epilepsy</subject><subject>Technology, Pharmaceutical - methods</subject><issn>0013-9580</issn><issn>1528-1167</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkElPwzAQhS0EomX5C8gnTqSMl9gJEgeoClQqixAIcbKyTKAlxcFuRfvvcWgkrlzGM_Z7z6OPEMpgwECq09mAxTyJGIv1gAPwASgd6mqL9LsHpbdJH4CJKI0T6JE972cAoJUWu6THuORCpKJPXm9tibWnlXV01ExrbPyaZp9lNyzsG36in_oz-oiNdQtaOTuni3ekd-Mb-mLdh3-3zQm9xHDny-yE3mZuXYeEA7JTZbXHw-7cJ89Xo6fhTTS5vx4PLyZRIRTjUZnlvEpR8kxAKWReFlpyJhXnIHiepblMBRSpiFWeFAKF0ICxKiBFlkipMrFPjje5jbNfS_QLM5_6AuuwA9qlN5orHWudBmGyERbOeu-wMo2bzsO2hoFpsZqZaemZFqtpsZpfrGYVrEfdH8t8juWfseMYBOcbwXegtv53sBk9jNtO_AAqF4Tn</recordid><startdate>200211</startdate><enddate>200211</enddate><creator>Stables, James P.</creator><creator>Bertram, Edward H.</creator><creator>White, H. Steve</creator><creator>Coulter, Douglas A.</creator><creator>Dichter, Marc A.</creator><creator>Jacobs, Margaret P.</creator><creator>Loscher, Wolfgang</creator><creator>Lowenstein, Daniel H.</creator><creator>Moshe, Solomon L.</creator><creator>Noebels, Jeffrey L.</creator><creator>Davis, Mirian</creator><general>Blackwell Science Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200211</creationdate><title>Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland</title><author>Stables, James P. ; Bertram, Edward H. ; White, H. Steve ; Coulter, Douglas A. ; Dichter, Marc A. ; Jacobs, Margaret P. ; Loscher, Wolfgang ; Lowenstein, Daniel H. ; Moshe, Solomon L. ; Noebels, Jeffrey L. ; Davis, Mirian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3612-dab2f9e42a30d34bdc74214622032ba9b4930c9356b8c3e3370e56c09e18446a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Animals</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Antiepileptogenesis</topic><topic>Child, Preschool</topic><topic>Disease Models, Animal</topic><topic>Drug Resistance</topic><topic>Epilepsy</topic><topic>Epilepsy - drug therapy</topic><topic>Epilepsy - etiology</topic><topic>Humans</topic><topic>Pediatric epilepsy</topic><topic>Resistant epilepsy</topic><topic>Technology, Pharmaceutical - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stables, James P.</creatorcontrib><creatorcontrib>Bertram, Edward H.</creatorcontrib><creatorcontrib>White, H. Steve</creatorcontrib><creatorcontrib>Coulter, Douglas A.</creatorcontrib><creatorcontrib>Dichter, Marc A.</creatorcontrib><creatorcontrib>Jacobs, Margaret P.</creatorcontrib><creatorcontrib>Loscher, Wolfgang</creatorcontrib><creatorcontrib>Lowenstein, Daniel H.</creatorcontrib><creatorcontrib>Moshe, Solomon L.</creatorcontrib><creatorcontrib>Noebels, Jeffrey L.</creatorcontrib><creatorcontrib>Davis, Mirian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Epilepsia (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stables, James P.</au><au>Bertram, Edward H.</au><au>White, H. Steve</au><au>Coulter, Douglas A.</au><au>Dichter, Marc A.</au><au>Jacobs, Margaret P.</au><au>Loscher, Wolfgang</au><au>Lowenstein, Daniel H.</au><au>Moshe, Solomon L.</au><au>Noebels, Jeffrey L.</au><au>Davis, Mirian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland</atitle><jtitle>Epilepsia (Copenhagen)</jtitle><addtitle>Epilepsia</addtitle><date>2002-11</date><risdate>2002</risdate><volume>43</volume><issue>11</issue><spage>1410</spage><epage>1420</epage><pages>1410-1420</pages><issn>0013-9580</issn><eissn>1528-1167</eissn><abstract>Purpose: The workshop explored the current problems, needs, and potential usefulness of existing methods of discovery of new therapies to treat epilepsy patients. Resistance to medical therapy (pharmacoresistance) and the development of epilepsy (epileptogenesis) are recognized as two of the major problems in epilepsy treatment today. At the same time, there is growing awareness that the development of new therapies has slowed, a trend that has economic and scientific roots. To move toward new and more effective therapies, novel approaches to therapy discovery are needed.
Methods: A workshop was held in March 2001 with the charge to develop a plan to move the exploration and discovery process forward. Participants from academia, government, and industry reviewed the current status of epilepsy therapy and explored the identification of potential new therapies.
Results: At the end of the 2‐day meeting, the panel made a series of recommendations. The two major recommendations were (a) to establish a means for continuing the examination of new approaches to therapy discovery, and (b) to identify models and approaches to therapy discovery that may identify treatments that are more successful than those available. Further recommendations were made to support the development of technology (miniaturization, computerization, video monitoring, etc.) to facilitate the use of the new models and to identify the mechanisms of therapy success and failure.
Conclusions: Understanding the epidemiology of therapy resistance and providing support for new approaches to therapy development were identified as key issues for introduction of new and more effective treatments.</abstract><cop>Boston, MA, USA</cop><pub>Blackwell Science Inc</pub><pmid>12423393</pmid><doi>10.1046/j.1528-1157.2002.06702.x</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0013-9580 |
ispartof | Epilepsia (Copenhagen), 2002-11, Vol.43 (11), p.1410-1420 |
issn | 0013-9580 1528-1167 |
language | eng |
recordid | cdi_proquest_miscellaneous_72675779 |
source | Wiley Free Content; MEDLINE; IngentaConnect Free/Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Animals Anticonvulsants - therapeutic use Antiepileptogenesis Child, Preschool Disease Models, Animal Drug Resistance Epilepsy Epilepsy - drug therapy Epilepsy - etiology Humans Pediatric epilepsy Resistant epilepsy Technology, Pharmaceutical - methods |
title | Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T03%3A33%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Models%20for%20Epilepsy%20and%20Epileptogenesis:%20Report%20from%20the%20NIH%20Workshop,%20Bethesda,%20Maryland&rft.jtitle=Epilepsia%20(Copenhagen)&rft.au=Stables,%20James%E2%80%83P.&rft.date=2002-11&rft.volume=43&rft.issue=11&rft.spage=1410&rft.epage=1420&rft.pages=1410-1420&rft.issn=0013-9580&rft.eissn=1528-1167&rft_id=info:doi/10.1046/j.1528-1157.2002.06702.x&rft_dat=%3Cproquest_cross%3E72675779%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72675779&rft_id=info:pmid/12423393&rfr_iscdi=true |